Hepatitis B virus reactivation with rituximab-containing regimen (Q26830484)

Yamamoto Y

2

1 reference

Shimono J

3

1 reference

Ohhigashi H

4

1 reference

Teshima T

5

1 reference

language of work or name

1 reference

27 November 2013

1 reference

World Journal of Hepatology

published in

0 references

volume

5

1 reference

page(s)

612-20

1 reference

issue

11

1 reference

Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Reactivation of hepatitis B virus with rituximab.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Occult hepatitis B virus infection and its clinical implications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

31 May 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Hepatitis B infection in patients with lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I11.612

Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3847944

Fatal HBV reactivation in a subject with anti-HBs and anti-HBc

28 November 2018

1 reference

12 December 2020

Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation

1 reference

12 December 2020

1 reference

12 December 2020

Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder

1 reference

12 December 2020

HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine

1 reference

12 December 2020

Occult hepatitis B virus infection

1 reference

12 December 2020

Chronic hepatitis B: update of recommendations

1 reference

12 December 2020

Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy

1 reference

12 December 2020

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab

1 reference

12 December 2020

Re-treatment of relapsed indolent B-cell lymphoma with rituximab

1 reference

12 December 2020